Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

131 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
PR
Transcript : Regulus Therapeutics Inc. - Special Call
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Transcript : Regulus Therapeutics Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 10:25 AM
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
AQ
Transcript : Regulus Therapeutics Inc. - Special Call
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Transcript : Regulus Therapeutics Inc. - Special Call
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
PR
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
PR
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
PR
Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board
CI
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
PR
Regulus Therapeutics Strengthens Research and Development Leadership
AQ
Regulus Therapeutics Strengthens Research & Development Leadership
PR
Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development
CI
Zura Bio Limited Announces Executive Changes
CI
Metacrine, Inc. Announces Board Changes
CI
JATT Acquisition Corp’s Proposed Business Combination With Zura Bio Limited Declared Effective by US SEC
BU
METACRINE, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Equillium, Inc. (NasdaqGM:EQ) cancelled the acquisition of Metacrine, Inc. from a group of shareholders.
CI
Metacrine Reports Third-Quarter 2022 Results
GL
Metacrine Reports Third-Quarter 2022 Results
GL
Transcript : Equillium, Inc., Metacrine, Inc. - M&A Call
Equillium to Acquire Metacrine in All-Stock Transaction
BU
Equillium, Inc. Appoints Preston Klassen Board of Directors
CI
Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. from a group of shareholders.
CI
METACRINE : REPORTS SECOND-QUARTER 2022 RESULTS - Form 8-K
PU
Metacrine Reports Second-Quarter 2022 Results
AQ
Metacrine Reports First-Quarter 2022 Results
GL
Metacrine Reports First-Quarter 2022 Results
GL
METACRINE : REPORTS FOURTH-QUARTER 2021 RESULTS - Form 8-K
PU
Metacrine Reports Fourth-Quarter 2021 Results
GL
Metacrine Reports Fourth-Quarter 2021 Results
GL
METACRINE, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
METACRINE : Announces executive leadership changes - Form 8-K
PU
METACRINE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
Metacrine Announces Executive Leadership Changes
GL
METACRINE : UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN - Form 8-K
PU
Metacrine Updates IBD Clinical Development Strategy and Implements Restructuring Plan
AQ
Metacrine : SEPARATION AND CONSULTING AGREEMENT - Form 8-K
PU
METACRINE : ANNOUNCES RESIGNATION OF CHIEF MEDICAL OFFICER - Form 8-K
PU
Metacrine Announces Resignation of Chief Medical Officer
AQ
Metacrine, Inc. Announces Resignation of Hubert C. Chen as Chief Medical Officer
CI
METACRINE REPORTS THIRD-QUARTER 2021 RESULTS - Form 8-K
PU
Metacrine Reports Third-Quarter 2021 Results
AQ
METACRINE : REPORTS INTERIM RESULTS FOR MET642 PHASE 2A TRIAL IN PATIENTS WITH NASH AND ANNOUNCES A STRATEGIC RE-PRIORITIZATION OF ITS CLINICAL DEVELOPMENT PROGRAMS - Form 8-K
PU
Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
GL
Metacrine : Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
GL
Metacrine : to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
AQ
No results for this search
  1. Stock Market
  2. Advanced search
  3. Preston Klassen
  4. News